← Browse by Condition
Medical Condition

primary peritoneal transitional cell carcinoma

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 3

ClinicalMetric tracks all active clinical trials for primary peritoneal transitional cell carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — primary peritoneal transitional cell carcinoma Clinical Trials

How many clinical trials are currently recruiting for primary peritoneal transitional cell carcinoma?
ClinicalMetric currently tracks 1 actively recruiting clinical trials for primary peritoneal transitional cell carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 1. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for primary peritoneal transitional cell carcinoma?
primary peritoneal transitional cell carcinoma research spans Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a primary peritoneal transitional cell carcinoma clinical trial?
Eligibility criteria for primary peritoneal transitional cell carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 3
1
Top Sponsors
M.D. Anderson Cancer Center 1 trial

Recruiting Clinical Trials

NCT04575935 Phase 3
Recruiting
Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
Enrollment
580 pts
Location
United States, Canad...
Sponsor
M.D. Anderson Cancer Center
View Trial →

Related Conditions

advanced ovarian carcinoma (1) fallopian tube clear cell adenocarcinoma (1) fallopian tube endometrioid tumor (1) fallopian tube serous neoplasm (1) fallopian tube transitional cell carcinoma (1) ovarian clear cell adenocarcinoma (1) ovarian endometrioid adenocarcinoma (1) ovarian serous adenocarcinoma (1) ovarian transitional cell carcinoma (1) primary peritoneal clear cell adenocarcinoma (1) primary peritoneal endometrioid adenocarcinoma (1) primary peritoneal serous adenocarcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology